Pregled bibliografske jedinice broj: 1136071
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? // Transfusion clinique et biologique, 28 (2021), 3; 264-270 doi:10.1016/j.tracli.2021.04.004 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1136071 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
COVID-19 convalescent plasma as long-term therapy in
immunodeficient patients?
Autori
Rnjak, Dina ; Ravlić, Sanda ; Šola, Ana-Marija ; Halassy, Beata ; Šemnički, Joško ; Šuperba, Martina ; Hećimović, Ana ; Kurolt, Ivan-Christian ; Kurtović, Tihana ; Mačak Šafranko, Željka ; Polančec, Denis ; Bendelja, Krešo ; Mušlin, Tatjana ; Jukić, Irena ; Vuk, Tomislav ; Zenić, Lucija ; Artuković, Marinko
Izvornik
Transfusion clinique et biologique (1246-7820) 28
(2021), 3;
264-270
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
COVID-19 ; convalescent plasma ; immunodeficiency ; infective virus-neutralization assay ; neutralizing antibody ; SARS-CoV-2
Sažetak
Abstract Objectives: The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 infection in a patient with a history of nasopharyngeal diffuse large B-cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV2 neutralizing antibodies in a patient plasma during the course of therapy. Materials and methods: Besides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti- SARS-CoV-2 immunoglobulin (human), were quantified in a time- dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations. Results: The waves of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Besides the patient's lack of own humoral immune system, immunophenotyping analysis revealed also the reduced level of helper T-lymphocytes and immune exhaustion of monocytes. Conclusion: Therapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 infection into a manageable chronic disease.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
HRZZ-IP-CORONA-IP-CORONA-2020-04-2053 - Stvaranje preduvjeta za uvođenje SARS-CoV-2 seroterapije u Hrvatskoj (Halassy, Beata, HRZZ - 2020-04) ( CroRIS)
EK-KK.01.1.1.01.0006 - Jačanje kapaciteta CERVIRVAC-a za istraživanja u virusnoj imunologiji i vakcinologiji (Jonjić, Stipan, EK ) ( CroRIS)
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Hrvatski zavod za transfuzijsku medicinu,
Dječja bolnica Srebrnjak,
Sveučilište u Zagrebu
Profili:
Lucija Zenić
(autor)
Ana Hećimović
(autor)
Krešo Bendelja
(autor)
Tihana Kurtović
(autor)
Marinko Artuković
(autor)
Irena Jukić
(autor)
Beata Halassy
(autor)
Tomislav Vuk
(autor)
Ivan-Christian Kurolt
(autor)
Sanda Ravlić
(autor)
Denis Polančec
(autor)
Željka Mačak Šafranko
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE